Drugs & Targets FDA grants Rare Pediatric Disease designation for THIO in pediatric high-grade gliomas January 17, 2025Vol.51 No.02
Conversation with The Cancer Letter After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency January 10, 2025Vol.51 No.01By Paul Goldberg
FreeTrials & Tribulations New colorectal cancer screening strategies must advance the standard of care January 10, 2025Vol.51 No.01By Paul J. Limburg
Drugs & Targets FDA issues draft guidance on including tissue biopsies in clinical trials January 10, 2025Vol.51 No.01
Drugs & Targets FDA approves Ensacove for ALK-positive locally advanced or metastatic NSCLC January 10, 2025Vol.51 No.01
Drugs & Targets FDA approves Tevimbra + chemo for first-line treatment of gastric and GEJ cancers January 10, 2025Vol.51 No.01
Drugs & Targets FDA approves Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma January 10, 2025Vol.51 No.01
Drugs & Targets FDA approves Ryoncil for steroid-refractory acute graft versus host disease in pediatric patients January 10, 2025Vol.51 No.01
Drugs & Targets FDA approves Opdivo and Opdivo Qvantig for subcutaneous injection January 10, 2025Vol.51 No.01
Drugs & Targets FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation January 10, 2025Vol.51 No.01
